The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis

DİNÇER İ., Ergin A., Kocagoz T.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol.23, no.4, pp.408-411, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 4
  • Publication Date: 2004
  • Doi Number: 10.1016/j.ijantimicag.2003.09.023
  • Journal Name: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.408-411
  • Keywords: beta-lactam, beta-lactamases, M. tuberculosis, clavulanic acid, CLAVULANIC ACID, COMBINATION, AMOXICILLIN, SUSCEPTIBILITY, ANTIBIOTICS, ETHAMBUTOL
  • Ankara University Affiliated: No

Abstract

In vitro activity of beta-lactam antibiotics and their beta-lactamase inhibitor combinations were evaluated for their activity against clinical isolates of Mycobacterium tuberculosis and M. tuberculosis H37Ra. Agar dilution, the BACTEC 460 system and P-lactamase activity tests were used. Results using the BACTEC 460 and enzyme activity tests showed the best beta-lactamase inhibitor for M. tuberculosis H37Ra to be clavulanic acid. Cefazolin-clavulanic acid gave the lowest minimal inhibitory concentration (MIC) values using dilution tests and M. tuberculosis H37Ra. p-Lactam antibiotics were combined with clavulanic acid and tested for in vitro activity against 50 selected multidrug-resistant (MDR) and 50 susceptible clinical isolates. Seventy-four percent of the isolates were inhibited by cefazolin-clavulanic acid combination. These results suggested that an appropriate combination of p-lactam and p-lactamase inhibitors might be useful in the treatment of tuberculosis due to multidrug-resistant strains. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.